ILMN Illumina, Inc.

309.574.37 (+1.43%)
Close: September 20, 2019

305.20-4.37 (-1.41%)
Pre-market

Quote

Previous Close
$309.57
Day Range
$302.82-$310.43
52 Week Range
$263.30-$380.76
Volume
1,785,335
Avg Volume
1,039,862
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$45.51B
Enterprise Value (EV)
$43.99B
PE Ratio
48.53
EV/EBITDA
41.42
Price/Sales
13.65
Price/Book
12.11
PEG Ratio
-

Financials

Revenue
$3.33B
Gross Profit
$2.33B
EBITDA
$1.06B
EPS, ttm
$6.38
Profit Margin
24.78%
Revenue/Employee
$456.58K
Next Earnings Date
10/22/2019 (30 days)
Debt to Equity
53%
Debt
$2.00B
Cash
$3.51B
Net Debt
-

Performance

Beta
1.47
200 Day Moving Avg
$309.63
50 Day Moving Avg
$292.02
52 Week Change
-13.57%
YTD Change
6.54%
1 Month Change
6.56%
3 Month Change
-14.38%
6 Month Change
-3.02%
1 Year Change
-13.57%
2 Year Change
75.88%
5 Year Change
129.30%

Share Count

Shares Outstanding
147.0M
Float
146.4M
Restricted Shares
562.4K
Restricted Shares, %
0.38%

Illumina, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Francis A. deSouza

Website: http://www.illumina.com

Description: Illumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Employees: 7,300